Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

Providence Cancer Institute

4805 NE Glisan, Suite 2N35, Portland, OR 97213

At Providence Cancer Institute, patients and families are offered extensive cancer services, including diagnostic imaging, state-of-the-art treatments, nationally-renowned research, and counseling and support. Doctors, surgeons, nurses, researchers, patient advocates, and other caregivers work together to treat cancer aggressively and ensure that no person has to face the challenge of a cancer diagnosis alone.

The institute’s comprehensive and compassionate cancer care includes:

  • Skilled cancer specialists who collaborate on diagnosis and treatment.
  • State-of-the art cancer therapies, including personalized medicine.
  • Access to clinical trials, including one of the largest programs for early-phase cancer clinical studies on the West Coast.
  • Integrative medicine to ease symptoms.
  • A nurse navigator to guide all aspects of care.
  • Cancer genetics experts, oncology social workers, and cancer support groups.
  • A cancer survivors’ clinic.

Website: Providence Cancer Institute
Contact: 503-215-6014

Trials at this location:

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Status: Open to Accrual
Read More

HCRN-BRE21-516

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

Status: Open to Accrual
Read More

HCRN-LUN18-357

Induction durvalumab followed by chemoradiation and consolidation durvalumab (MEDI4736) for stage III non-small cell lung cancer

Status: Closed to Accrual
Read More

HCRN-MEL16-252

Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252

Status: Closed to Accrual
Read More